BioSpace News Archive

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2022.

Rain Therapeutics Inc. reports financial results for the first quarter ended March 31, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.

Societal CDMO, Inc. announced that the company will release financial results for the first quarter 2022 after the market close on Wednesday, May 11, 2022.

Paratek Pharmaceuticals, Inc. reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022.

Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference at 3:20 p.m. PT on Wednesday, May 11, 2022.

BioAtla, Inc. announced its financial results for the first quarter ended March 31, 2022, and provided an interim topline data update from the mecbotamab vedotin Phase 2 study in sarcoma as well as an operational update on its ongoing clinical programs, including BA3011, ozuriftamab vedotin and CAB-CTLA-4 addressing multiple tumor types.

Cytokinetics, Incorporated reported financial results for the first quarter of 2022.

Allogene Therapeutics, Inc. provided a corporate update and reported financial results for the quarter ended March 31, 2022.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, reported financial results for the first quarter 2022.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the first quarter ended March 31, 2022.